IL17A and psoriasis: Bimekizumab was initially validated in the treatment of psoriasis, where comparative trials, including BE READY (bimekizumab vs. placebo) [88], BE VIVID (bimekizumab vs. ustekinumab) [89], BE RADIANT (bimekizumab vs. secukinumab) [90], and BE SURE (bimekizumab vs. adalimumab) [91], established its superior efficacy compared to anti-TNF agents and other anti-IL-17 therapies.